BELLUS Health to Present at the H.C. Wainwright Global Investment Conference
09/02/2021 - 07:00 AM
LAVAL, Quebec --(BUSINESS WIRE)--
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders, today announced that Roberto Bellini , BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company at the H.C. Wainwright Global Investment Conference .
Presentation Details:
Event: H.C. Wainwright 23rd Annual Global Investment Conference
Date/Time: Monday, September 13 th , 2021 at 7:00 a.m. ET
A webcast of the presentation may be accessed on the Events & Presentations page under the Investors & Media section of BELLUS Health's website at www.bellushealth.com . Following the event, an archived webcast will be available on the Company’s website.
About BELLUS Health ( www.bellushealth.com )
BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of RCC and chronic pruritus associated with AD.
RCC is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for RCC and treatment options are limited.
Chronic pruritus associated with AD is an irritating sensation that leads to scratching and persists for longer than 6 weeks in AD patients. It is estimated that up to 10% of adults in the United States suffer from AD – almost all report symptoms of pruritus with over 50% of patients attributing chronic pruritus as their most burdensome symptom. Despite currently available treatments targeting AD, there continues to be a lack of options specifically targeting the burden of pruritus in patients with AD.
View source version on businesswire.com : https://www.businesswire.com/news/home/20210902005114/en/
Ramzi Benamar
rbenamar@bellushealth.com
Media:
Julia Deutsch
jdeutsch@soleburytrout.com
Source: BELLUS Health Inc.
Bellus Health Inc
NASDAQ:BLU
BLU Rankings
N/A Ranked by Stock Gains
BLU Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
Canada
City
Laval
About BLU
bellus health is a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need. its lead project is blu-5937, a drug candidate for the treatment of chronic cough. bellus health also has economic interests in other partnered drug development projects. blu-5937 is a potent, highly selective, orally bioavailable small molecule antagonist of the p2x3 receptor, a clinically validated target for chronic cough. blu-5937 is a promising best-in-class drug candidate that has the potential to help millions of chronic cough patients who do not respond to current therapies. rights to blu-5937 were obtained under a license agreement with the neomed institute in february 2017. chronic cough is a cough that lasts more than eight weeks and is associated with significant adverse social, psychosocial and physical effects on quality of life. it is estimated that, in the united states alone, more than 2.7 million patients suffer from chronic cough that is
